Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform.

David J. Galbreath has received funding from the ESRC and AHRC. The new US president, Donald Trump, has only been in office for a few days, but he has already changed his tune on the war in ...